

## 1 **BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans**

2 Ugur Sahin<sup>1,2</sup>, Alexander Muik<sup>1</sup>, Isabel Vogler<sup>1</sup>, Evelyn Derhovanesian<sup>1</sup>, Lena M. Kranz<sup>1</sup>,  
3 Mathias Vormehr<sup>1</sup>, Jasmin Quandt<sup>1</sup>, Nicole Bidmon<sup>1</sup>, Alexander Ulges<sup>1</sup>, Alina Baum<sup>5</sup>, Kristen  
4 Pascal<sup>5</sup>, Daniel Maurus<sup>1</sup>, Sebastian Brachtendorf<sup>1</sup>, Verena Lörks<sup>1</sup>, Julian Sikorski<sup>1</sup>, Peter  
5 Koch<sup>1</sup>, Rolf Hilker<sup>1</sup>, Dirk Becker<sup>1</sup>, Ann-Kathrin Eller<sup>1</sup>, Jan Grützner<sup>1</sup>, Manuel Tonigold<sup>1</sup>,  
6 Carsten Boesler<sup>1</sup>, Corinna Rosenbaum<sup>1</sup>, Ludwig Heesen<sup>1</sup>, Marie-Cristine Kühnle<sup>1</sup>, Asaf Poran<sup>3</sup>,  
7 Jesse Z. Dong<sup>3</sup>, Ulrich Luxemburger<sup>1</sup>, Alexandra Kemmer-Brück<sup>1</sup>, David Langer<sup>1</sup>, Martin  
8 Bexon<sup>8</sup>, Stefanie Bolte<sup>1</sup>, Tania Palanche<sup>1</sup>, Armin Schultz<sup>7</sup>, Sybille Baumann<sup>7</sup>, Azita J. Mahiny<sup>1</sup>,  
9 Gábor Boros<sup>1</sup>, Jonas Reinholz<sup>1</sup>, Gábor T. Szabó<sup>1</sup>, Katalin Karikó<sup>1</sup>, Pei-Yong Shi<sup>6</sup>, Camila  
10 Fontes-Garfias<sup>6</sup>, John L. Perez<sup>4</sup>, Mark Cutler<sup>4</sup>, David Cooper<sup>4</sup>, Christos A. Kyratsous<sup>5</sup>, Philip  
11 R. Dormitzer<sup>4</sup>, Kathrin U. Jansen<sup>4</sup>, Özlem Türeci<sup>1</sup>

12

13 <sup>1</sup> BioNTech, An der Goldgrube 12, 55131 Mainz, Germany.

14 <sup>2</sup> TRON gGmbH – Translational Oncology at the University Medical Center of the Johannes  
15 Gutenberg, University Freiligrathstraße 12, 55131 Mainz, Germany.

16 <sup>3</sup> BioNTech US, 40 Erie Street, Suite 110, Cambridge, MA 02139, U.S.A.

17 <sup>4</sup> Pfizer, 401 N Middletown Rd., Pearl River, NY 10960, U.S.A.

18 <sup>5</sup> Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Rd, Tarrytown, NY 10591, U.S.A.

19 <sup>6</sup> University of Texas Medical Branch, Galveston, TX 77555, U.S.A.

20 <sup>7</sup> CRS Clinical Research Services Mannheim GmbH, Grenadierstrasse 1, 68167 Mannheim,  
21 Germany

22 <sup>8</sup> Bexon Clinical Consulting LLC, Upper Montclair, NJ 07043, U.S.A.

23

24 **Correspondence:** Ugur Sahin, BioNTech, An der Goldgrube 12, 55131 Mainz, Germany, Tel:  
25 +49 6131 9084 1801, Email: [Ugur.Sahin@biontech.de](mailto:Ugur.Sahin@biontech.de)

26

27 BNT162b2, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA  
28 (mRNA) encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike  
29 protein (S) stabilized in the prefusion conformation, has demonstrated 95% efficacy to prevent  
30 coronavirus disease 2019 (COVID-19). Recently, we reported preliminary BNT162b2 safety  
31 and antibody response data from an ongoing placebo-controlled, observer-blinded phase 1/2  
32 vaccine trial<sup>1</sup>. We present here antibody and T cell responses from a second, non-randomized  
33 open-label phase 1/2 trial in healthy adults, 19-55 years of age, after BNT162b2 prime/boost  
34 vaccination at 1 to 30 µg dose levels. BNT162b2 elicited strong antibody responses, with S-  
35 binding IgG concentrations above those in a COVID-19 human convalescent sample (HCS)  
36 panel. Day 29 (7 days post-boost) SARS-CoV-2 serum 50% neutralising geometric mean titers  
37 were 0.3-fold (1 µg) to 3.3-fold (30 µg) those of the HCS panel. The BNT162b2-elicited sera  
38 neutralised pseudoviruses with diverse SARS-CoV-2 S variants. Concurrently, in most  
39 participants, S-specific CD8<sup>+</sup> and T helper type 1 (TH1) CD4<sup>+</sup> T cells had expanded, with a high  
40 fraction producing interferon-γ (IFNγ). Using peptide MHC multimers, the epitopes recognised  
41 by several BNT162b2-induced CD8<sup>+</sup> T cells when presented on frequent MHC alleles were  
42 identified. CD8<sup>+</sup> T cells were shown to be of the early-differentiated effector-memory  
43 phenotype, with single specificities reaching 0.01-3% of circulating CD8<sup>+</sup> T cells. In summary,  
44 vaccination with BNT162b2 at well tolerated doses elicits a combined adaptive humoral and  
45 cellular immune response, which together may contribute to protection against COVID-19.

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 46 **Main**

### 47 **Introduction**

48 Given the high impact of the pandemic caused by the severe acute respiratory syndrome  
49 coronavirus 2 (SARS-CoV-2) on human society, the rapid development of safe and effectively  
50 prophylactic vaccines is of utmost importance.

51 Lipid nanoparticle (LNP) formulated messenger RNA (mRNA) vaccine technology delivers the  
52 precise genetic information of the immunogen to antigen presenting cells and elicits potent  
53 immune responses<sup>2</sup>. mRNA is transiently expressed, does not integrate into the genome, and is  
54 degraded by physiological pathways. mRNA vaccines are molecularly well defined, and are  
55 synthesized efficiently from DNA templates by *in vitro* transcription, which is cell- and animal-  
56 origin material-free<sup>3-5</sup>. mRNA production and LNP formulation are fast processes of high  
57 scalability, rendering this technology suitable for rapid vaccine development and pandemic  
58 vaccine supply<sup>6-8</sup>.

59 Within 'Project Lightspeed', the joint BioNTech-Pfizer COVID-19 RNA vaccine development  
60 program, two phase 1/2 umbrella trials, one in Germany (NCT04380701) and one in the USA  
61 (NCT04368728) investigate a total of four RNA-LNP vaccine candidates in. Recently, we  
62 reported preliminary clinical data from these studies on the two most advanced candidates  
63 BNT162b1<sup>9,10</sup> and BNT162b2<sup>1</sup>. Each candidate is an LNP-formulated, pharmacologically  
64 optimized<sup>11,12</sup>, N<sup>1</sup>-methylpseudouridine (m<sup>1</sup>Ψ) nucleoside-modified mRNA (modRNA)<sup>13</sup>  
65 administered intramuscularly as a prime-boost 21 days apart. BNT162b1 encodes a trimerized,  
66 secreted version of the receptor-binding domain (RBD) of S, whereas BNT162b2 encodes the  
67 full-length SARS-CoV-2 S stabilised in the prefusion conformation (P2 S)<sup>14</sup>.

68 BNT162b2 in a 30 µg two dose regimen has been selected for advancement into an ongoing  
69 phase 2/3 trial, guided by the totality of data obtained in the two phase 1/2 trials and NHP

70 challenge studies<sup>1,15</sup>. In the placebo-controlled, observer-blind USA phase 1/2 trial,  
71 immunisation of 18-55 and 65-83 year old participants with BNT162b2 at dose levels of up to  
72 30 µg was associated with generally mild to moderate local injection site reactions and  
73 systemic events such as fatigue, headache, and myalgia<sup>1</sup>. BNT162b2 elicited robust S1-binding  
74 immunoglobulin G (IgG) concentrations and SARS-CoV-2 neutralising titers. Geometric mean  
75 50% neutralising titers (GMTs) of sera drawn from younger and older adults seven days after  
76 the second dose of 30 µg BNT162b2 were 3.8-fold and 1.6-fold, respectively, the GMT of a  
77 panel of COVID-19 convalescent human sera. Complementing and expanding the published  
78 findings in the USA phase 1/2 trial, we now provide data from the German trial (NCT04380701,  
79 EudraCT: 2020- 001038-36). We report immunogenicity and safety of prime-boost vaccination  
80 with 1, 10, 20 and 30 µg BNT162b2 in participants 19-55 years of age, including neutralising  
81 antibody GMTs up to day 85 after the first dose (approximately two months after the booster  
82 dose) and detailed characterisation of T cell responses, including the first identification of  
83 epitopes recognised by CD8<sup>+</sup> T cells induced by a COVID-19 vaccine.

#### 84 **Study design and analysis sets**

85 Participants 19-55 years of age were vaccinated with BNT162b2 in Germany (Extended Data  
86 Fig. 1). Participants' mean age was 40 years; 56% were female, and all were Caucasian  
87 (Extended Data Table 1). Twelve participants per dose cohort were assigned to receive a  
88 priming dose of 1, 10, 20 or 30 µg on day 1 and a booster dose on day 22 (Extended Data Table  
89 2). One individual each in the 1 µg dose cohort and the 10 µg dose cohort discontinued prior to  
90 the boost. In each dose group, antibody levels and virus neutralisation titers were assessed in  
91 10 to 12 participants per timepoint (up to day 85, 63 days post-boost), and peripheral blood  
92 mononuclear cells (PBMCs) from 8 to 10 participants were analysed for cellular immune  
93 responses at baseline and day 29 (7 days post-boost) (Extended Data Table 2).

## 94 **Safety and tolerability**

95 Briefly, no serious adverse events (SAE) and no withdrawals due to related adverse events  
96 (AEs) were observed at any dose level. Local reactions, predominantly pain at the injection  
97 site, were mild to moderate (grade 1 and 2) and were similar in frequency and severity after the  
98 priming and booster doses (Extended Data Fig. 2a and Extended Data Table 3a). The most  
99 common systemic AEs were fatigue followed by headache and only two participants reported  
100 fever, which was mild (Extended Data Fig. 2b and Extended Data Table 3b). Transient chills  
101 were more common after the boost, dose-dependent, and occasionally severe. Muscle pain and  
102 joint pain were also more common after the boost and showed dose-dependent severity. There  
103 were no grade 4 reactions. Generally, reactions had their onset within 24 hours of immunisation,  
104 peaked on the day after immunisation, and mostly resolved within 2-3 days. Reactions did not  
105 require treatment or could be managed with simple measures (e.g. paracetamol).

106 No clinically significant changes in routine clinical laboratory values occurred after BNT162b2  
107 vaccination. In line with previous reports for RNA-based vaccines<sup>1,9,10,16</sup>, a mild drop of blood  
108 lymphocyte counts (without concomitant neutropenia) and an increase in C-reactive protein  
109 (CRP) were observed, both transient, dose-dependent and within or close to laboratory normal  
110 levels (Extended Data Fig. 3). Both effects are considered pharmacodynamic markers for the  
111 mode-of-action of RNA vaccines: blood lymphocyte counts transiently decrease as the  
112 lymphocytes redistribute into lymphoid tissues in response to innate immune stimulation<sup>17</sup>, and  
113 CRP is a downstream effect of innate immune modulation<sup>18-21</sup>.

## 114 **Characterization of vaccine-induced antibody response**

115 S1- and RBD-binding IgG concentrations and SARS-CoV-2 neutralising titers were assessed  
116 at baseline (day 1), 7 and 21 days after the BNT162b2 priming dose (days 8 and 22), and 7, 21,  
117 28 and 63 days after the booster dose (days 29, 43 and 50; day 85 for all dose levels except  
118 1 µg) (Fig. 1, Extended Data Fig. 4, Extended Data Table 2).

119 The vaccine elicited strong antibody responses. Twenty-one days after the priming dose,  
120 geometric mean concentrations (GMCs) of S1-binding IgG had increased in all dose cohorts,  
121 with S1-binding IgG GMCs in the range of 49-1,161 U/mL and evidence of a dose level-  
122 dependent response only between the 1 µg and 10 µg dose levels (Fig. 1a). Seven days after the  
123 booster dose (day 29), S1-binding IgG GMCs showed a strong booster response ranging from  
124 691-8,279 U/mL. Antibody levels decreased over time, but with S1-binding antibody GMCs  
125 still in the range of 1,384-2,991 U/mL at day 85 (63 days after the boost), and hence well above  
126 that observed in a panel of sera from SARS-CoV-2 convalescent patients (631 U/mL). Similar  
127 observations were made using only the RBD domain as the target antigen (Extended Data  
128 Fig. 4).

129 SARS-CoV-2 50% neutralising geometric mean titers (GMTs) increased modestly and only in  
130 a proportion of participants after the priming dose of BNT162b2 (Fig. 1b). By seven days after  
131 the booster dose, neutralising GMTs had increased substantially to 169, 195 or 312 in  
132 participants immunised with 10 µg, 20 µg or 30 µg BNT162b2, respectively. The 1 µg dose  
133 level elicited only a minimal neutralizing response (GMT of 25 at seven days after the boost).  
134 On day 43 (21 days after the boost), participants vaccinated with BNT162b2 dose levels  
135 between 10 and 30 µg had virus neutralizing GMTs between 108 and 166. Importantly, SARS-  
136 CoV-2 neutralising GMTs remained stable up to day 85 (63 days after the boost) with titers  
137 ranging from 120 to 181, and thus were 1.3- to 1.9-fold the convalescent serum panel  
138 neutralising GMT of 94.

139 S1-binding IgG GMCs after the boost showed a gradual decline, which is typical of the pattern  
140 of proliferation followed by contraction of B cells cognately activated by either natural infection  
141 or vaccination<sup>25</sup>. In contrast, GMTs initially decreased after the boost but stabilized around day  
142 43, which implies selection and affinity maturation of functional antibodies.

143 Neutralising antibody GMTs correlated strongly with S1-binding IgG GMCs (Fig. 1c). In  
144 summary, neutralizing responses and antigen-binding IgG responses elicited by BNT162b2 in  
145 this study largely mirrored those observed in the U.S.A. study, and for the first time cover  
146 extended follow-up until day 85.

147 A panel of 18 SARS-CoV-2 RBD variants identified through publicly available information<sup>24</sup>  
148 and the dominant non-RBD S variant D614G<sup>25</sup> were evaluated as targets in pseudovirus  
149 neutralisation assays. Sera collected seven days after the booster dose of BNT162b2 showed  
150 high neutralising titers to each of the SARS-CoV-2 S variants (Fig. 1d), demonstrating the  
151 breadth of the neutralising response against circulating strains.

## 152 **Prevalence and magnitude of vaccine-induced T cell responses**

153 T cell responses of 37 BNT162b2 immunised participants from whom sufficient peripheral  
154 blood mononuclear cells (PBMCs) were available were analysed pre-vaccination (day 1) and  
155 seven days after the booster dose (day 29) by direct ex vivo IFN $\gamma$  enzyme-linked  
156 immunosorbent spot (ELISpot) assay (Fig. 2, Extended Data Fig. 5, Extended Data Table 2).  
157 SARS-CoV-2 S is composed of a signal peptide (aa 1-13), the N-terminal S1 protease fragment  
158 (aa 14-685), and the C-terminal S2 protease fragment (aa 686-1273). S1 contains the RBD (aa  
159 319-541), which binds to the host receptor, and S2 mediates fusion between the viral envelope  
160 and cell membrane. To deconvolute reactivity against S, CD4<sup>+</sup> or CD8<sup>+</sup> T cell effectors were  
161 stimulated overnight with overlapping peptides representing different portions of the wild-type  
162 sequence of SARS-CoV-2 S, namely N-terminal pools ‘S pool 1’ (aa 1-643) and ‘RBD’ (aa 1-  
163 16 fused to aa 327-528 of S), and the C-terminal ‘S pool 2’ (aa 633-1273).

164 Seven days after the boost with BNT162b2 at any of the doses, robustly expanded SARS-CoV-  
165 2 S-specific CD4<sup>+</sup> T cells were detectable in all 37 participants (Fig. 2a, Extended Data Fig.  
166 5a). In 34 of these participants, comparison to pre-vaccination PBMCs was possible. Thirty of  
167 the 34 subjects (88.2%) had de novo (not existent at baseline) CD4<sup>+</sup> T cell responses against

168 both S pool 1 and S pool 2 of SARS-CoV-2. One participant had de novo response only against  
169 S pool 2. The remaining three participants had de novo responses against S pool 1 and low  
170 numbers of pre-existing S pool 2-reactive CD4<sup>+</sup> T cells. In two of these three participants, the  
171 pre-existing responses against S pool 2 were amplified by vaccination (from 91 and 188  
172 spots/10<sup>6</sup> cells pre-vaccination to 1391 and 965 spots after vaccination, respectively), whereas  
173 in one of the three participants, the pre-existing responses against S pool 2 remained stable (53  
174 to 140 spots/10<sup>6</sup> cells). In conclusion, these data demonstrate that in 94.1% (32/34) of  
175 participants, two doses of BNT162b2 induce poly-epitopic CD4<sup>+</sup> T cell responses (de novo or  
176 amplified) directed against both N- and C-terminal portions of S and thus against epitopes  
177 outside the RBD (Extended Data Fig. 5b).

178 Although for dose levels  $\geq 10$   $\mu$ g the magnitude of CD4<sup>+</sup> T cell responses did not appear to be  
179 dose-dependent, it varied between individuals. In the strongest responders, the S-specific CD4<sup>+</sup>  
180 T cell responses were more than 10-fold of the individual memory responses to common viruses  
181 and recall antigens (those from cytomegalovirus, Epstein Barr virus, influenza virus and tetanus  
182 toxoid) (Fig. 2b, c).

183 Vaccine-induced S-specific CD8<sup>+</sup> T cell responses were detected in 34 of 37 vaccinated  
184 participants (91.9%). The majority were strong responses (Fig. 2a, Extended Data Fig. 5a)  
185 comparable to individual memory responses against cytomegalovirus (CMV), Epstein Barr  
186 virus (EBV) and influenza virus (Fig. 2b, c). De novo S-specific CD8<sup>+</sup> T cell responses were  
187 induced in 33 participants, these were either directed against both (22 participants), or one of  
188 the S pools (S pool 1 in ten participants, and S pool 2 in two participants), indicating a  
189 preponderance of a poly-epitopic response including non-RBD S-specific T cells (Extended  
190 Data Fig. 5b). In seven participants, pre-existing CD8<sup>+</sup> T cell responses to S pool 2 were  
191 detected that were not further augmented by vaccination. Six out of these seven participants  
192 had a concurrent de novo response to pool 1 of S, which in strength did not differ significantly



193 from those observed in individuals without pre-existing responses to S pool 2 (Extended Data  
194 Fig. 5c). Of note, the strongest responses (higher than third quartile) against S pool 1 among  
195 the 34 participants with detectable CD8<sup>+</sup> T cell responses were observed in those without pre-  
196 existing S pool 2-specific responses.

197 The magnitude of S-specific CD4<sup>+</sup> T cell responses correlated positively with S1-binding IgG  
198 (Extended Data Fig. 6a), and, in line with the concept of intramolecular help<sup>26</sup>, also with the  
199 strength of S-specific CD8<sup>+</sup> T cell responses (Extended Data Fig. 6b). S-specific CD8<sup>+</sup> T cell  
200 responses also correlated positively with S1-binding IgG (Extended Data Fig. 6c), indicating a  
201 convergent development of the humoral and cellular adaptive immunity.

## 202 **Polarisation of vaccine-induced T cell responses**

203 To assess functionality and polarisation of S-specific T cells, cytokines secreted in response to  
204 stimulation with S pool 1, S pool 2 and RBD pool were determined by intracellular staining  
205 (ICS) for IFN $\gamma$ , IL-2 and IL-4 specific responses in pre- and post-vaccination PBMCs of 37  
206 BNT162b2-immunised participants (Extended Data Table 2). A considerable fraction of  
207 vaccine-induced, S-specific CD4<sup>+</sup> T cells secreted IFN $\gamma$ , IL-2, or both, while T cells secreting  
208 the TH2 cytokine IL-4 were barely detectable (Fig. 3a-c, Extended Data Fig. 5d, e). Vaccine-  
209 induced S-specific CD8<sup>+</sup> T cells secreted predominantly IFN $\gamma$  and lower levels of IL-2 in  
210 response to S pool 1 and S pool 2 stimulation. Fractions of IFN $\gamma$ <sup>+</sup> CD8<sup>+</sup> T cells specific to S  
211 pool 1 constituted up to about 1% of total peripheral blood CD8<sup>+</sup> T cells (Fig. 3d). Of note,  
212 several of the analysed participants ( $n=3$  in the 20  $\mu$ g dose cohort and  $n=3$  in the 30  $\mu$ g dose  
213 cohort) displayed pre-existing S pool 2 specific CD8<sup>+</sup> T cell responses, which in 5 out of the  
214 6 participants were not further amplified after vaccination. A strong pre-existing S pool 2  
215 specific IFN $\gamma$ <sup>+</sup> CD4<sup>+</sup> T cell response was detectable in one participant (20  $\mu$ g dose cohort) (Fig.  
216 3c).



217 In both assay systems, cytokine production of CD4<sup>+</sup> as well as CD8<sup>+</sup> T cells in response to  
218 peptide pools comprising the full SARS-CoV-2 S exceeded the responses against the RBD  
219 peptide pool, further confirming the poly-epitopic nature of T cell responses elicited by  
220 BNT162b2. The mean fraction of BNT162b2-induced S-specific IFN $\gamma$ <sup>+</sup> or IL-2<sup>+</sup> CD4<sup>+</sup> and  
221 CD8<sup>+</sup> T cells within total circulating T cells was higher than that detected in eighteen control  
222 subjects who had recovered from COVID-19 (HCS) (Fig. 3c, d).

### 223 **Epitope specificity and phenotype of CD8<sup>+</sup> T cells**

224 CD8<sup>+</sup> T cell responses were characterised on the epitope level in three BNT162b2 vaccinated  
225 participants. To this aim, pre- and post-vaccination PBMCs were stained with individualised  
226 peptide/MHC multimer staining cocktails for flow cytometry analysis. Twenty-three (4 for  
227 HLA-B\*0702, 19 for HLA-A\*2402), 14 (HLA-B\*3501) and 23 (7 for HLA-B\*4401, 16 for  
228 HLA-A\*0201) diverse peptide/MHC allele pairs were used for participants 1, 2 and 3,  
229 respectively. This approach identified de novo induced CD8<sup>+</sup> T cell reactivities against multiple  
230 epitopes for each participant, adding up to a total of eight different epitope/MHC pairs spread  
231 across the full length of S (Fig. 4a, c). The magnitude of epitope-specific T cell responses ranged  
232 between 0.01-3.09% of peripheral CD8<sup>+</sup> T cells, and the most profound expansion was observed  
233 for HLA-A\*0201 YLQPRTFLL (3.09% multimer<sup>+</sup> of CD8<sup>+</sup>), HLA-A\*2402 QYIKWPWYI  
234 (1.27% multimer<sup>+</sup> of CD8<sup>+</sup>) and HLA-B\*3501 QPTESIVRF (0.17% multimer<sup>+</sup> of CD8<sup>+</sup>).

235 Whereas the pMHC multimer approach probes a discrete subset of potential reactivities, bulk  
236 IFN $\gamma$ <sup>+</sup> CD8<sup>+</sup> T cell responses against full S determined by ELISpot and ICS are considered to  
237 comprehensively capture the full poly-epitopic T cell response. However, comparison of both  
238 data sets indicated that a functional T cell assay may underestimate the true extent of the cellular  
239 immune response (Extended Data Fig. 5f).

240 Phenotyping of the identified pMHC multimer<sup>+</sup> S antigen-experienced CD8<sup>+</sup> T cell specificities  
241 revealed an early differentiated effector memory phenotype characterised by low expression of

242 CCR7 and CD45RA and high expression of the costimulatory molecules CD28 and CD27.  
243 CD8<sup>+</sup> T cells also expressed markers associated with cognate activation, such as CD38, HLA-  
244 DR and PD-1 (Fig. 4b).

## 245 **Discussion**

246 Effectors of the adaptive immune system have complementary roles in the defense of viral  
247 infections. While neutralising antibodies are the first line of defense, CD8<sup>+</sup> cytotoxic T  
248 lymphocytes (CTLs) contribute to virus clearance from intracellular compartments that are  
249 inaccessible to neutralising antibodies. Antigen-specific CD4<sup>+</sup> T cells have immune  
250 orchestrating functions, including provision of cognate help to B cells and CD8<sup>+</sup> T cells, support  
251 of memory generation, as well as indirect (*e.g.* via IFN $\gamma$ ) or direct (against MHC class II-  
252 expressing target cells) cytotoxic activity.

253 There is broad consensus reflected in the design of ongoing clinical trials that a COVID-19  
254 vaccine should induce antibodies to SARS-CoV-2 S. However, it is not yet known if antibody  
255 responses will be sufficient for full and long-lasting protective immunity to SARS-CoV-2, and  
256 what the contribution of SARS-CoV-2-specific T cells may be.

257 Previous experience with the closely related first SARS-CoV suggests that T cells prevent  
258 severe forms of the disease<sup>27</sup> and may be associated with long-term protection<sup>28,29</sup>. For the novel  
259 SARS-CoV-2, an understanding of mechanisms of immunity from studies of infected and  
260 convalescent individuals is only beginning to emerge. An increasing amount of data supports a  
261 role of T cell immune responses<sup>30-32</sup>. COVID19 patients with critical disease states were  
262 reported to lack S1-reactive CD4<sup>+</sup> T cells<sup>33</sup>. Cases of asymptomatic virus exposure have been  
263 associated with cellular immune responses without seroconversion, indicating that SARS-CoV-  
264 2 specific T cells could be relevant in disease control even in the absence of neutralising  
265 antibodies<sup>29</sup>.

266 We report here that vaccination with BNT162b2 induces a coordinated immune response with  
267 SARS-CoV-2 S-specific neutralising antibodies, CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, and immune-  
268 modulatory cytokines such as IFN $\gamma$ .

269 All participants vaccinated with BNT162b2 mounted de novo S-specific CD4<sup>+</sup> T cell responses  
270 and almost 92% of participants mounted CD8<sup>+</sup> T cell responses, as detected with an ex vivo  
271 ELISpot assay. The magnitude of the T cell responses varied inter-individually and showed no  
272 clear dose dependency. Even with the lowest dose of 1  $\mu$ g BNT162b2, most of the vaccinated  
273 participants demonstrated robust expansion of CD4<sup>+</sup> and CD8<sup>+</sup> T cells. T cell responses were  
274 directed against RBD, S1 and S2 regions of S, indicating immune recognition of multiple  
275 independent MHC I and II epitopes, which was one of the reasons to favour BNT162b2 over  
276 BNT162b1.

277 Expression of IFN $\gamma$  and IL-2 but only low levels of IL-4 in BNT162b2-induced CD4<sup>+</sup> T cells  
278 indicated a T<sub>H</sub>1 profile and the absence of a potentially deleterious T<sub>H</sub>2 immune response.

279 While all CD8<sup>+</sup> T cell responses against the S1 subunit of S were de novo and not detected at  
280 baseline, pre-existing immune responses against the S2 subunit were identified in several  
281 individuals. The S1 fragment has less sequence similarity to the corresponding seasonal  
282 coronavirus sequences than the S2 fragment does, indicating that we may have detected pre-  
283 existing cross-reactive CD8<sup>+</sup> T cells<sup>34,35</sup>.

284 pMHC multimer technology enabled the identification of S epitopes recognised by vaccine-  
285 induced CD8<sup>+</sup> T cells as well as direct quantification of the respective epitope-specific T cells.  
286 The cumulative T cell frequencies in each participant exceeded the overall T cell response  
287 measured in ELISpot and ICS assays, indicating that those assays underestimate the true  
288 magnitude of the poly-epitopic response. Single peptide analyses are well known to yield higher  
289 T cell frequencies as compared to functional T cell assays that stimulate with peptide pools,  
290 with a multitude of immunogenic epitopes competing. A high proportion of induced CD8<sup>+</sup> T

291 cells were early differentiated effector memory cells. This favourable phenotype has the  
292 potential to respond rapidly, but has a limited capacity to produce IFN $\gamma$ , and thus is less likely  
293 to be detected in functional T cell assays. Previous studies have identified epitopes in SARS-  
294 CoV-2 S against which infected individuals raise CD8<sup>+</sup> T cells<sup>36,37</sup>. To our knowledge, this is  
295 the first report of epitopes recognised by COVID-19 vaccine-induced T cells. Of note, the  
296 immunodominant HLA-A\*02:01 restricted peptide YLQPRTFLL identified in our study has  
297 previously been described in convalescent COVID-19 patients<sup>36,37</sup>.

298 In addition to providing new insights into T cell responses, this study reproduces our previous  
299 findings in the U.S.A trial<sup>1</sup>, and confirms a benign safety profile and robust induction of  
300 antibody responses, with the latter being followed up for a longer period, up to day 85 (63 days  
301 post-boost). Prime/boost vaccination with 10 to 30  $\mu$ g of BNT162b2 elicited GMTs that, after  
302 an initial decline, remained stable up to day 85 in the range of, or higher than, GMTs in COVID-  
303 19 recovered individuals. BNT162b2 immune sera efficiently neutralised 19 pseudotyped  
304 viruses (18 of which enter cells using an S protein with a different RBD variant, and one of  
305 which uses the dominant S variant D614G), indicating the potential for broad BNT162b2-  
306 elicited protection against reported mutations<sup>1,9,10</sup>.

307 Limitations of our clinical study include the small sample size, the lack of representation of  
308 populations of interest (*e.g.* older adults, other ethnicities, immunocompromised individuals  
309 and pediatric populations), and limited availability of blood samples for a more in-depth T cell  
310 analysis.

311 Typically antigen-activated B and T cells go through proliferation, followed by rebound  
312 contraction with a gradual decline in numbers before entering a sustained memory phase<sup>22,23</sup>,  
313 and the short-term follow up presented in this paper does not allow for extrapolation of long-  
314 term durability of the immune responses. Whereas it is encouraging that BNT162b2 robustly  
315 activates antigen-specific humoral and as cellular immune effector systems, it is not clear

316 whether this immune response pattern will protect from SARS-CoV-2 infection and prevent  
317 COVID-19. These questions will be addressed by the ongoing clinical program, which includes  
318 longer term follow-up of participants in the two ongoing phase 1/2 trials, a dedicated immune  
319 biomarker trial to further dissect the composite elements of the immune response, and the  
320 ongoing phase 2/3 study with efficacy endpoints.

## 321 **Acknowledgements**

322 We thank Mikael Dolsten, Pfizer Chief Scientific Officer, for advice during drafting of the  
323 manuscript. We thank C. Anders, C. Anft, N. Beckmann, K. Bissinger, P. Cienskowski, K.  
324 Clarke, C. Ecker, A. Engelman, M. Fierek, D. Harjanto, A. Heinen, M. Hossainzadeh, S. Jäggle,  
325 L. Jeck, O. Kahl, D. Kallin, M. Knezovic, T. Kotur, M. Kretschmer, A. Kruithof, J. Mc Gee, B.  
326 Mehlhase, C. Müller, S. Murphy, L.-M. Schmid, K. Schmoldt, R. Schulz, L. Srinivasan, M.  
327 Vehreschild, T. Weisenburger and S. Wessel for technical support, project management and  
328 advice. We thank P. Koch for data management and analysis. We thank O. Kistner, S.  
329 Liebscher, J. Loschko and K. Swanson for expert advice. We thank Judith Absalon for  
330 manuscript advice. We thank the CRS Team (Mannheim and Berlin) for study conduct: S.  
331 Armani, M. Berse, M. Casjens, B. Ehrlich, F. Seitz, M. Streckebein. We thank W. Kalina, I.  
332 Scully, and the Pfizer Vaccines Clinical Assays Team and the Pfizer Aviation Team for  
333 technical and logistical support of serology analyses. We thank GISAID Nucleotide database  
334 for sharing of SARS-CoV-2 complete genome sequences.

## 335 **Author Contributions**

336 U.S. conceived and conceptualised the work and strategy supported by Ö.T. Experiments were  
337 planned or supervised by N.B., E.D., C. F.-G, C.A.K., U.L., A.M., J.Q., P.-Y.S., A.U. and I.V..  
338 A.B., N.B., D.C, M.C., C. F.-G, K.P., J.Q., A.U. and P.-Y.S. performed experiments. D.B., S.  
339 Brachtendorf, E.D., P.R.D., J.G., K.U.J., A.-K.E., P.K., M.T., L.M.K., M.-C.K., V.L., A.M.,  
340 J.Q., J.S., N.B., A.U., I.V. and M.V. analysed data. A.P. prioritised epitopes for multimer assay.  
341 J.Z.D. supervised manufacturing and delivery of peptides for multimer assay. D.M. planned  
342 and supervised dashboards for analysis of clinical trial data. R.H. was responsible for data  
343 normalization and adaption. C.B, L.H. and C.R. were responsible for biomarker and R&D

344 program management. G.B., K.K., A.J.M., J.R. and G.T.S. optimised mRNA characteristics.  
345 A.K-B., S. Baumann, A.S., D.L., M.B., S. Bolte, and T.P. coordinated operational conduct of  
346 the clinical trial. J.L.P. advised on the trial. U.S., Ö.T., supported by M.B., N.B., E.D., P.R.D.,  
347 K.U.J., L.M.K., A.M., A.U., I.V. and M.V., interpreted data and wrote the manuscript. All  
348 authors supported the review of the manuscript.

## 349 **Competing interests**

350 The authors declare: U.S. and Ö.T. are management board members and employees at  
351 BioNTech SE (Mainz, Germany); A. K.-B., A.-K.E., A.U., C.R., D.B., P.K., D.L., D.M., E.D.,  
352 J.G., J. S., M.-C.K., R.H., S. Bolte, S. Brachtendorf, T.P., U.L. and V.L. are employees at  
353 BioNTech SE; A.J.M., A.M., G.B., G.T.S., I.V., J.R., J.Q., K.K., L.M.K., N.B., and M.V. are  
354 employees at BioNTech RNA Pharmaceuticals GmbH; A.P. and J.Z.D are employees at  
355 BioNTech US; M.B. is an employee at Bexon Clinical Consulting LLC. A.B., C.A.K. and K.P.  
356 are employees of Regeneron Pharmaceuticals Inc; A.M., K.K., Ö.T. and U.S. are inventors on  
357 patents and patent applications related to RNA technology and COVID-19 vaccine; A.K.-B.,  
358 J.Z.D., A.J.M., A.M., C.R., G.B., D.B., D.L., E.D., I.V., J.G., K.K., L.M.K., A.P., M.V., N.B.,  
359 Ö.T., R.H., S. Bolte, U.L. and U.S. have securities from BioNTech SE; D.C., M.C., P.R.D.,  
360 K.U.J. and J.L.P. are employees at Pfizer and may have securities from Pfizer; C.A.K. is an  
361 officer at Regeneron Pharmaceuticals, Inc; A.B., C.A.K. and K.P. have securities from  
362 Regeneron Pharmaceuticals, Inc; C.F.-G. and P.-Y.S. received compensation from Pfizer to  
363 perform the neutralisation assay; no other relationships or activities that could appear to have  
364 influenced the submitted work.



## 365 **Funding**

366 BioNTech is the Sponsor of the study and responsible for the design, data collection, data  
367 analysis, data interpretation, and writing of the report. Pfizer advised on the study and the  
368 manuscript, generated serological data, and contracted for the generation of serological data.  
369 The corresponding authors had full access to all the data in the study and had final responsibility  
370 for the decision to submit the data for publication. All study data were available to all authors.  
371 This study was not supported by any external funding at the time of submission.

## 372 **Additional Information**

373 Supplementary Information is available for this paper.

374 Correspondence and requests for materials should be addressed to Ugur Sahin.

## 375 **Materials and Methods**

### 376 **Clinical trial design.**

377 Study BNT162-01 (NCT04380701) is an ongoing, umbrella-type first-in-human, phase 1/2,  
378 open-label, dose-ranging clinical trial to assesses the safety, tolerability, and immunogenicity  
379 of ascending dose levels of various intramuscularly administered BNT162 mRNA vaccine  
380 candidates in healthy men and non-pregnant women 18 to 55 years (amended to add 56-85  
381 years) of age. The principle endpoints of the study are safety and immunogenicity. Key  
382 exclusion criteria included previous clinical or microbiological diagnosis of COVID-19; receipt  
383 of medications to prevent COVID-19; previous vaccination with any coronavirus vaccine; a  
384 positive serological test for SARS-CoV-2 IgM and/or IgG; and a SARS-CoV-2 nucleic acid  
385 amplification test (NAAT)-positive nasal swab; increased risk for severe COVID-19; and  
386 immunocompromised individuals.

387 The presented data are from the BNT162b2-immunised healthy adults 19 to 55 years of age  
388 exposed to dose levels 1, 10, 20 or 30 µg. The data are based on a preliminary analysis (data  
389 extraction date of 23 October 2020 for safety and antibody analysis, 16 October 2020 and 24  
390 November 2020 for T cell analysis [intracellular cytokine staining and ELISpot, respectively])  
391 and are focused on analysis of vaccine-induced immunogenicity descriptively summarised at  
392 the various time points, and on reactogenicity. All participants with data available were  
393 included in the immunogenicity analyses. This part of the study was performed at one site in  
394 Germany with 12 healthy participants per dose level in a dose-escalation/de-escalation design.  
395 Sentinel dosing was performed in each dose-escalation cohort. Progression in that cohort and  
396 dose escalation required data review by a safety review committee. Participants received a  
397 BNT162b2 priming dose on day 1, and a booster dose on day 22±2 (on day 28 for one  
398 participant from the 10 µg dose cohort). Serum for antibody assays was obtained on day 1 (pre-  
399 prime), 8±1 (post-prime), 22±2 (pre-boost), 29±3, 43±4 and 50±4 (post-boost). PBMCs for T

400 cell studies were obtained on day 1 (pre-prime) and 29±3 (post-boost) (Extended Data Fig. 1).  
401 Follow-up of participants is ongoing and includes assessment of antibody and T cell responses  
402 at later time points. Reactogenicity was assessed by patient diary. Two participants discontinued  
403 prior to the booster dose due to study drug-unrelated withdrawal (participant in the 1 µg dose  
404 cohort) and an adverse event (participant of the 10 µg dose cohort) (upper respiratory  
405 syndrome), respectively. The trial was carried out in Germany in accordance with the  
406 Declaration of Helsinki and Good Clinical Practice Guidelines and with approval by an  
407 independent ethics committee (Ethik-Kommission of the Landesärztekammer Baden-  
408 Württemberg, Stuttgart, Germany) and the competent regulatory authority (Paul-Ehrlich  
409 Institute, Langen, Germany). All participants provided written informed consent.

#### 410 **Manufacturing of RNA.**

411 BNT162b2 incorporates a Good Manufacturing Practice (GMP)-grade mRNA drug substance  
412 that encodes the trimerised SARS-CoV-2 S glycoprotein RBD antigen. The RNA is generated  
413 from a DNA template by *in vitro* transcription in the presence of 1-methylpseudouridine-5'-  
414 triphosphate (m1ΨTP; Thermo Fisher Scientific) instead of uridine-5'-triphosphate (UTP).  
415 Capping is performed co-transcriptionally using a trinucleotide cap 1 analogue ((m<sup>2</sup><sub>7,3'</sub>-  
416 <sup>o</sup>)Gppp(m<sup>2</sup><sub>7,3'</sub>-O)ApG; TriLink). The antigen-encoding RNA contains sequence elements that  
417 increase RNA stability and translation efficiency in human dendritic cells<sup>11,12</sup>. The mRNA is  
418 formulated with lipids to obtain the RNA-LNP drug product. The vaccine was transported and  
419 supplied as a buffered-liquid solution for IM injection and was stored at -80 °C.

#### 420 **Proteins and peptides.**

421 Two pools of 15-mer peptides overlapping by 11 amino acids (aa) and together covering the  
422 whole sequence of wild-type SARS-CoV-2 S (S pool 1 featuring aa 1-643, S pool 2 featuring  
423 aa 633-1273) and one pool covering the SARS-CoV-2 RBD (aa 327-528) with the signal  
424 peptide of S (aa 1-16) fused to its N-terminus were used for ex vivo stimulation of PBMCs for

425 flow cytometry and IFN $\gamma$  ELISpot. CEF (CMV, EBV, influenza virus; human leukocyte antigen  
426 [HLA] class I epitope peptide pool) and CEFT (CMV, EBV, influenza virus, tetanus toxoid;  
427 HLA class II epitope peptide pool) were used as controls for general T cell reactivity and to  
428 benchmark the magnitude of memory T cell responses. All the above peptides were obtained  
429 from JPT Peptide Technologies. The 8-12 amino acid long peptides used in the easYmer assays  
430 were produced at BioNTech US.

#### 431 **Human convalescent serum and PBMC panel.**

432 Human SARS-CoV-2 infection/COVID-19 convalescent sera ( $n=38$ ) were drawn from donors  
433 18-83 years of age at least 14 days after PCR-confirmed diagnosis and at a time when the  
434 participants were asymptomatic. The mean age of the donors was 45 years. Neutralising GMTs  
435 in subgroups of the donors were as follows: symptomatic infections, 90 ( $n=35$ ); asymptomatic  
436 infections, 156 ( $n=3$ ); hospitalized, 618 ( $n=1$ ). Sera were obtained from Sanguine Biosciences  
437 (Sherman Oaks, CA), the MT Group (Van Nuys, CA) and Pfizer Occupational Health and  
438 Wellness (Pearl River, NY). Human SARS-CoV-2 infection/COVID-19 convalescent PBMC  
439 samples ( $n=18$ ) were collected from donors 22-79 years of age 30-62 days after PCR-confirmed  
440 diagnosis, when donors were asymptomatic. PBMC donors had asymptomatic or mild  
441 infections ( $n=16$ , clinical score 1 and 2) or had been hospitalized ( $n=2$ , clinical score 4 and 5).  
442 Blood samples were obtained from the Frankfurt University Hospital.

#### 443 **Cell culture and primary cell isolation.**

444 Vero cells (American Type Culture Collection [ATCC] CCL-81) and Vero E6 cells (ATCC  
445 CRL-1586) were cultured in Dulbecco's modified Eagle's medium (DMEM) with  
446 GlutaMAX™ (Gibco) supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich). Cell  
447 lines were tested for mycoplasma contamination after receipt and before expansion and  
448 cryopreservation. PBMCs were isolated by Ficoll-Paque™ PLUS (Cytiva) density gradient  
449 centrifugation and cryopreserved prior to analysis.

450 **S1- and RBD-binding IgG assay.**

451 Recombinant SARS-CoV-2 S1 or RBD containing a C-terminal Avitag™ (Acro Biosystems)  
452 were bound to streptavidin-coated Luminex microspheres. Heat-inactivated participant sera  
453 were diluted 1:500, 1:5,000, and 1:50,000. Following an overnight incubation at 2-8 °C while  
454 shaking, plates were washed in a solution containing 0.05% Tween-20. A secondary  
455 fluorescently labelled goat anti-human polyclonal antibody (Jackson Labs) was added for  
456 90 minutes at room temperature while shaking, before plates were washed once more in a  
457 solution containing 0.05% Tween-20. Data were captured as median fluorescent intensities  
458 (MFIs) using a Bioplex200 system (Bio-Rad) and converted to U/mL antibody concentrations  
459 using a reference standard curve with arbitrarily assigned concentrations of 100 U/mL and  
460 accounting for the serum dilution factor. The reference standard was composed of a pool of five  
461 convalescent serum samples obtained >14 days after COVID-19 PCR diagnosis and was diluted  
462 sequentially in antibody-depleted human serum. Three dilutions were used to increase the  
463 likelihood that at least one result for any sample would fall within the useable range of the  
464 standard curve. Assay results were reported in U/mL of IgG. The final assay results were  
465 expressed as the geometric mean concentration of all sample dilutions that produced a valid  
466 assay result within the assay range.

467 **SARS-CoV-2 neutralisation assay.**

468 The neutralisation assay used a previously described strain of SARS-CoV-2 (USA\_WA1/2020)  
469 that had been rescued by reverse genetics and engineered by the insertion of an mNeonGreen  
470 (mNG) gene into open reading frame 7 of the viral genome<sup>38</sup>. This reporter virus generates  
471 similar plaque morphologies and indistinguishable growth curves from wild-type virus. Viral  
472 master stocks ( $2 \times 10^7$  PFU/mL) were grown in Vero E6 cells as previously described<sup>38</sup>. With  
473 patient convalescent sera, the fluorescent neutralisation assay produced comparable results to  
474 the conventional plaque reduction neutralisation assay<sup>39</sup>. Serial dilutions of heat-inactivated

475 sera were incubated with the reporter virus ( $2 \times 10^4$  PFU per well to yield a 10-30% infection  
476 rate of the Vero CCL81 monolayer) for 1 hour at 37 °C before inoculating Vero CCL81 cell  
477 monolayers (targeted to have 8,000 to 15,000 cells in a central field of each well at the time of  
478 seeding, 24 hours before infection) in 96-well plates to allow accurate quantification of infected  
479 cells. Total cell counts per well were enumerated by nuclear stain (Hoechst 33342) and  
480 fluorescent virally infected foci were detected 16-24 hours after inoculation with a Cytation 7  
481 Cell Imaging Multi-Mode Reader (BioTek) with Gen5 Image Prime version 3.09. Titers were  
482 calculated in GraphPad Prism version 8.4.2 by generating a 4-parameter (4PL) logistical fit of  
483 the percent neutralisation at each serial serum dilution. The 50% neutralisation titre (VNT<sub>50</sub>)  
484 was reported as the interpolated reciprocal of the dilution yielding a 50% reduction in  
485 fluorescent viral foci.

#### 486 **VSV-SARS-CoV-2 S variant pseudovirus neutralisation assay.**

487 Vesicular stomatitis virus (VSV)-SARS-CoV-2-S pseudoparticle generation and neutralisation  
488 assays were performed as previously described<sup>24</sup>. Briefly, human codon optimized SARS-CoV-  
489 2 S (GenBank: MN908947.3) was synthesised (Genscript) and cloned into an expression  
490 plasmid. SARS-CoV-2 complete genome sequences were downloaded from GISAID  
491 nucleotide database (<https://www.gisaid.org>). Sequences were curated, and genetic diversity of  
492 the S-encoding gene was assessed across high quality genome sequences using custom  
493 pipelines. Amino acid substitutions were cloned into the S expression plasmid using site-  
494 directed mutagenesis. HEK293T cells (ATCC CRL-3216) were seeded (culture medium:  
495 DMEM high glucose [Life Technologies] supplemented with 10% heat-inactivated FBS (Life  
496 Technologies) and penicillin/streptomycin/L-glutamine [Life Technologies]) and transfected  
497 the following day with S expression plasmid using Lipofectamine LTX (Life Technologies)  
498 following the manufacturer's protocol. At 24 hours post-transfection at 37 °C, cells were

499 infected with the VSV $\Delta$ G:mNeon/VSV-G diluted in Opti-MEM (Life Technologies) at a  
500 multiplicity of infection of 1. Cells were incubated 1 hour at 37 °C, washed to remove residual  
501 input virus and overlaid with infection medium (DMEM high glucose supplemented with 0.7%  
502 Low IgG bovine serum albumin [BSA, Sigma], sodium pyruvate [Life Technologies] and 0.5%  
503 Gentamicin [Life Technologies]). After 24 hours at 37 °C, the medium containing VSV-SARS-  
504 CoV-2-S pseudoparticles was collected, centrifuged at 3000 x g for 5 minutes to clarify and  
505 stored at -80 °C until further use.

506 For pseudovirus neutralisation assays, Vero cells (ATCC CCL-81) were seeded in 96-well  
507 plates in culture medium and allowed to reach approximately 85% confluence before use in the  
508 assay (24 hours later). Sera were serially diluted 1:2 in infection medium starting with a 1:300  
509 dilution. VSV-SARS-CoV-2-S pseudoparticles were diluted 1:1 in infection medium for a  
510 fluorescent focus unit (ffu) count in the assay of ~1000. Serum dilutions were mixed 1:1 with  
511 pseudoparticles for 30 minutes at room temperature prior to addition to Vero cells and  
512 incubation at 37 °C for 24 hours. Supernatants were removed and replaced with PBS (Gibco),  
513 and fluorescent foci were quantified using the SpectraMax i3 plate reader with MiniMax  
514 imaging cytometer (Molecular Devices). Neutralisation titers were calculated in GraphPad  
515 Prism version 8.4.2 by generating a 4-parameter logistical (4PL) fit of the percent neutralisation  
516 at each serial serum dilution. The 50% pseudovirus neutralisation titre (pVNT<sub>50</sub>) was reported  
517 as the interpolated reciprocal of the dilution yielding a 50% reduction in fluorescent viral foci.

#### 518 **IFN $\gamma$ ELISpot.**

519 IFN $\gamma$  ELISpot analysis was performed ex vivo (without further in vitro culturing for expansion)  
520 using PBMCs depleted of CD4<sup>+</sup> and enriched for CD8<sup>+</sup> T cells (CD8<sup>+</sup> effectors) or depleted of



521 CD8<sup>+</sup> and enriched for CD4<sup>+</sup> T cells (CD4<sup>+</sup> effectors). Tests were performed in duplicate and  
522 with a positive control (anti-CD3 monoclonal antibody CD3-2 [1:1,000; Mabtech]).  
523 Multiscreen filter plates (Merck Millipore) pre-coated with IFN $\gamma$ -specific antibodies  
524 (ELISpotPro kit, Mabtech) were washed with PBS and blocked with X-VIVO 15 medium  
525 (Lonza) containing 2% human serum albumin (CSL-Behring) for 1-5 hours. Per well,  $3.3 \times 10^5$   
526 effector cells were stimulated for 16-20 hours with three overlapping peptide pools representing  
527 different portions of the wild-type sequence of SARS-CoV-2 S (N-terminal pools S pool 1 [aa  
528 1-643] and RBD [aa1-16 fused to aa 327-528], and the C-terminal S pool 2 [aa 633-1273]).  
529 Bound IFN $\gamma$  was visualised using a secondary antibody directly conjugated with alkaline  
530 phosphatase followed by incubation with 5-bromo-4-chloro-3'-indolyl phosphate (BCIP)/ nitro  
531 blue tetrazolium (NBT) substrate (ELISpotPro kit, Mabtech). Plates were scanned using an AID  
532 Classic Robot ELISPOT Reader and analysed by AID ELISPOT 7.0 software (AID Autoimmun  
533 Diagnostika). Spot counts were displayed as mean values of each duplicate. T cell responses  
534 stimulated by peptides were compared to effectors incubated with medium only as a negative  
535 control using an in-house ELISpot data analysis tool (EDA), based on two statistical tests  
536 (distribution-free resampling) according to Moodie et al.<sup>40,41</sup>, to provide sensitivity while  
537 maintaining control over false positives.

538 To account for varying sample quality reflected in the number of spots in response to anti-CD3  
539 antibody stimulation, a normalisation method was applied, enabling direct comparison of spot  
540 counts and strength of response between individuals. This dependency was modelled in a log-  
541 linear fashion with a Bayesian model including a noise component (unpublished). For a robust  
542 normalisation, each normalisation was sampled 10,000 times from the model and the median  
543 taken as normalised spot count value. Likelihood of the model:  $\log \lambda_E = \alpha \log \lambda_P + \log \beta_j +$   
544  $\sigma \epsilon$ , where  $\lambda_E$  is the normalized spot count of the sample;  $\alpha$  is a stable factor (normally  
545 distributed) common among all positive controls  $\lambda_P$ ;  $\beta_j$  is a sample  $j$  specific component

546 (normally distributed); and  $\sigma\varepsilon$  is the noise component, of which  $\sigma$  is Cauchy distributed, and  $\varepsilon$   
547 is Student's-t distributed.  $\beta_j$  ensures that each sample is treated as a different batch.

#### 548 **Flow cytometry.**

549 Cytokine-producing T cells were identified by intracellular cytokine staining. PBMCs thawed  
550 and rested for 4 hours in OpTmizer medium supplemented with 2  $\mu\text{g}/\text{mL}$  DNase I (Roche),  
551 were restimulated with different portions of the wild-type sequence of SARS-CoV-2 S in  
552 peptide pools described in the ELISpot section (2  $\mu\text{g}/\text{mL}/\text{peptide}$ ; JPT Peptide Technologies)  
553 in the presence of GolgiPlug (BD) for 18 hours at 37 °C. Controls were treated with DMSO-  
554 containing medium. Cells were stained for viability and surface markers (CD3 BV421, 1:250;  
555 CD4 BV480, 1:50; CD8 BB515, 1:100; all BD Biosciences) in flow buffer (DPBS [Gibco]  
556 supplemented with 2% FBS [Biochrom], 2 mM ethylenediaminetetraacetic acid [EDTA;  
557 Sigma-Aldrich]) for 20 minutes at 4 °C. Afterwards, samples were fixed and permeabilised  
558 using the Cytofix/Cytoperm kit according to manufacturer's instructions (BD Biosciences).  
559 Intracellular staining (CD3 BV421, 1:250; CD4 BV480, 1:50; CD8 BB515, 1:100; IFN $\gamma$  PE-  
560 Cy7, 1:50 [for HCS]; IFN $\gamma$  BB700, 1:250 [for participants]; IL-2 PE, 1:10; IL-4 APC, 1:500;  
561 all BD Biosciences) was performed in Perm/Wash buffer for 30 minutes at 4 °C. Samples were  
562 acquired on a fluorescence-activated cell sorter (FACS) VERSE instrument (BD Biosciences)  
563 and analysed with FlowJo software version 10.6.2 (FlowJo LLC, BD Biosciences). S- and  
564 RBD-specific cytokine production was corrected for background by subtraction of values  
565 obtained with dimethyl sulfoxide (DMSO)-containing medium. Negative values were set to  
566 zero. Cytokine production in Figure 4b was calculated by summing up the fractions of all CD4<sup>+</sup>  
567 T cells positive for either IFN $\gamma$ , IL-2 or IL-4, setting this sum to 100% and calculating the  
568 fraction of each specific cytokine-producing subset thereof. Pseudocolor plot axes are in log<sub>10</sub>  
569 scale.

570 **Peptide/MHC multimer staining.**

571 In order to select MHC-class I epitopes for multimer analysis, a mass spectrometry-based  
572 binding and presentation predictor<sup>42,43</sup> was applied to 8-12 amino acid long peptide sequences  
573 from the Spike glycoprotein derived from the GenBank reference sequence for SARS-CoV-2  
574 (accession: NC\_045512.2, [https://www.ncbi.nlm.nih.gov/nuccore/NC\\_045512](https://www.ncbi.nlm.nih.gov/nuccore/NC_045512)) and paired  
575 with 18 MHC-class-I alleles with >5% frequency in the European population. Top predicted  
576 epitopes were identified by setting thresholds to the binding percent-rank ( $\leq 1\%$ ) and  
577 presentation scores ( $\geq 10^{-2.2}$ ). Peptides were manufactured at >90% purity. pMHC complexes  
578 were refolded with the easYmer technology (easYmer® kit, ImmuneAware Aps), and complex  
579 formation was validated in a bead-based flow cytometry assay according to the manufacturer's  
580 instructions<sup>44,45</sup>. Combinatorial labeling was used for dissecting the antigen specificity of T  
581 cells utilizing two-color combinations of five different fluorescent labels to enable detection of  
582 up to ten different T cell populations per sample<sup>46</sup>. For tetramerisation, streptavidin (SA)-  
583 fluorochrome conjugates were added: SA BV421, SA BV711, SA PE, SA PE-Cy7, SA APC  
584 (all BD Biosciences). For three BNT162b2 vaccinated participants, individualized pMHC  
585 multimer staining cocktails contained up to ten pMHC complexes, with each pMHC complex  
586 encoded by a unique two-color combination. PBMCs ( $2 \times 10^6$ ) were stained ex vivo for 20  
587 minutes at room temperature with each pMHC multimer cocktail at a final concentration of  
588 4 nM in Brilliant Staining Buffer Plus (BSB Plus [BD Horizon™]). Surface and viability  
589 staining was carried out in flow buffer (DPBS [Gibco] with 2% FBS [Biochrom], 2 mM EDTA  
590 [Sigma-Aldrich]) supplemented with BSB Plus for 30 minutes at 4 °C (CD3 BUV395, 1:50;  
591 CD45RA BUV563, 1:200; CD27 BUV737, 1:200; CD8 BV480, 1:200; CD279 BV650, 1:20;  
592 CD197 BV786, 1:15; CD4 BB515, 1:50; CD28 BB700, 1:100; CD38 PE-CF594, 1:600; HLA-  
593 DR APC-R700, 1:150; all BD Biosciences; DUMP channel: CD14 APC-eFluor780, 1:100;  
594 CD16 APC-eFluor780, 1:100; CD19 APC-eFluor780, 1:100; fixable viability dye eFluor780,

595 1:1,667; all ThermoFisher Scientific). Cells were fixed for 15 minutes at 4 °C in 1x Stabilization  
596 Fixative (BD), acquired on a FACSymphony™ A3 flow cytometer (BD Biosciences) and  
597 analysed with FlowJo software version 10.6.2 (FlowJo LLC, BD Biosciences). CD8<sup>+</sup> T cell  
598 reactivities were considered positive, when a clustered population was observed that was  
599 labelled with only two pMHC multimer colors.

#### 600 **Statistical analysis.**

601 The sample size for the reported part of the study was not based on statistical hypothesis testing.  
602 All participants with data available were included in the safety and immunogenicity analyses.  
603 The statistical method of aggregation used for the analysis of antibody concentrations and titers  
604 is the geometric mean and the corresponding 95% CI. Employing the geometric mean accounts  
605 for non-normal distribution of antibody concentrations and titers spanning several orders of  
606 magnitude. Spearman correlation was used to evaluate the monotonic relationship between non-  
607 normally distributed data sets.

608 All statistical analyses were performed using GraphPad Prism software version 8.4.2.

#### 609 **Data availability.**

610 The data that support the findings of this study are available from the corresponding author  
611 upon reasonable request. Upon completion of this clinical trial, summary-level results will be  
612 made public and shared in line with data sharing guidelines.

## 613 **References**

- 614 1. Walsh, E. E. *et al.* Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine  
615 Candidates. *N. Engl. J. Med.* NEJMoa2027906 (2020). doi:10.1056/NEJMoa2027906
- 616 2. Pardi, N. *et al.* Nucleoside-modified mRNA vaccines induce potent T follicular helper  
617 and germinal center B cell responses. *J. Exp. Med.* **215**, 1571–1588 (2018).
- 618 3. Rauch, S., Jasny, E., Schmidt, K. E. & Petsch, B. New Vaccine Technologies to Combat  
619 Outbreak Situations. *Front. Immunol.* **9**, (2018).
- 620 4. Pardi, N. *et al.* Expression kinetics of nucleoside-modified mRNA delivered in lipid  
621 nanoparticles to mice by various routes. *J. Control. Release* **217**, 345–351 (2015).
- 622 5. Sahin, U., Kariko, K. & Tureci, O. mRNA-based therapeutics - developing a new class  
623 of drugs. *Nat. Rev. Drug Discov.* **13**, 759–780 (2014).
- 624 6. Pardi, N. *et al.* Nucleoside-modified mRNA immunization elicits influenza virus  
625 hemagglutinin stalk-specific antibodies. *Nat. Commun.* **9**, 3361 (2018).
- 626 7. Pardi, N. *et al.* Zika virus protection by a single low-dose nucleoside-modified mRNA  
627 vaccination. *Nature* **543**, 248–251 (2017).
- 628 8. Pardi, N. *et al.* Characterization of HIV-1 nucleoside-modified mRNA vaccines in  
629 rabbits and rhesus macaques. *Mol. Ther. - Nucleic Acids* **15**, 36–47 (2019).
- 630 9. Mulligan, M. J. *et al.* Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults.  
631 *Nature* (2020). doi:10.1038/s41586-020-2639-4
- 632 10. Sahin, U. *et al.* COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell  
633 responses. *Nature* (2020). doi:10.1038/s41586-020-2814-7
- 634 11. Holtkamp, S. *et al.* Modification of antigen-encoding RNA increases stability,  
635 translational efficacy, and T-cell stimulatory capacity of dendritic cells. *Blood* **108**,

- 636 4009–4017 (2006).
- 637 12. Orlandini von Niessen, A. G. *et al.* Improving mRNA-Based Therapeutic Gene Delivery  
638 by Expression-Augmenting 3' UTRs Identified by Cellular Library Screening. *Mol. Ther.*  
639 **27**, 824–836 (2019).
- 640 13. Karikó, K. *et al.* Incorporation of pseudouridine into mRNA yields superior  
641 nonimmunogenic vector with increased translational capacity and biological stability.  
642 *Mol. Ther.* **16**, 1833–40 (2008).
- 643 14. Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion  
644 conformation. *Science* **367**, 1260–1263 (2020).
- 645 15. BNT162b vaccines are immunogenic and protect non-human primates against SARS-  
646 CoV-2. *Nature in revisio*, (2020).
- 647 16. Sahin, U. *et al.* An RNA vaccine drives immunity in checkpoint-inhibitor-treated  
648 melanoma. *Nature* **585**, 107–112 (2020).
- 649 17. Kamphuis, E., Junt, T., Waibler, Z., Forster, R. & Kalinke, U. Type I interferons directly  
650 regulate lymphocyte recirculation and cause transient blood lymphopenia. *Blood* **108**,  
651 3253–61 (2006).
- 652 18. Tsai, M. Y. *et al.* Effect of influenza vaccine on markers of inflammation and lipid  
653 profile. *J. Lab. Clin. Med.* **145**, 323–7 (2005).
- 654 19. Taylor, D. N. *et al.* Development of VAX128, a recombinant hemagglutinin (HA)  
655 influenza-flagellin fusion vaccine with improved safety and immune response. *Vaccine*  
656 **30**, 5761–9 (2012).
- 657 20. Doener, F. *et al.* RNA-based adjuvant CV8102 enhances the immunogenicity of a  
658 licensed rabies vaccine in a first-in-human trial. *Vaccine* **37**, 1819–1826 (2019).


- 659 21. Destexhe, E. *et al.* Evaluation of C-reactive protein as an inflammatory biomarker in  
660 rabbits for vaccine nonclinical safety studies. *J. Pharmacol. Toxicol. Methods* **68**, 367–  
661 73 (2013).
- 662 22. Kaech, S. M., Wherry, E. J. & Ahmed, R. Effector and memory T-cell differentiation:  
663 implications for vaccine development. *Nat. Rev. Immunol.* **2**, 251–62 (2002).
- 664 23. Pérez-Mazliah, D., Ndungu, F. M., Aye, R. & Langhorne, J. B-cell memory in malaria:  
665 Myths and realities. *Immunol. Rev.* **293**, 57–69 (2020).
- 666 24. Baum, A. *et al.* Antibody cocktail to SARS-CoV-2 spike protein prevents rapid  
667 mutational escape seen with individual antibodies. *Science* **369**, 1014–1018 (2020).
- 668 25. Zhang, L. *et al.* The D614G mutation in the SARS-CoV-2 spike protein reduces S1  
669 shedding and increases infectivity. *bioRxiv Prepr. Serv. Biol.* (2020). doi:bioRxiv:  
670 10.1101/2020.06.12.148726
- 671 26. Sette, A. *et al.* Selective CD4+ T cell help for antibody responses to a large viral  
672 pathogen: deterministic linkage of specificities. *Immunity* **28**, 847–58 (2008).
- 673 27. Cameron, M. J., Bermejo-Martin, J. F., Danesh, A., Muller, M. P. & Kelvin, D. J. Human  
674 immunopathogenesis of severe acute respiratory syndrome (SARS). *Virus Res.* **133**, 13–  
675 9 (2008).
- 676 28. Tang, F. *et al.* Lack of peripheral memory B cell responses in recovered patients with  
677 severe acute respiratory syndrome: a six-year follow-up study. *J. Immunol.* **186**, 7264–8  
678 (2011).
- 679 29. Channappanavar, R., Fett, C., Zhao, J., Meyerholz, D. K. & Perlman, S. Virus-specific  
680 memory CD8 T cells provide substantial protection from lethal severe acute respiratory  
681 syndrome coronavirus infection. *J. Virol.* **88**, 11034–44 (2014).
- 682 30. Ni, L. *et al.* Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in



- 683 COVID-19 Convalescent Individuals. *Immunity* **52**, 971-977.e3 (2020).
- 684 31. Grifoni, A. *et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans  
685 with COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489-1501.e15 (2020).
- 686 32. Giménez, E. *et al.* SARS-CoV-2-reactive interferon- $\gamma$ -producing CD8<sup>+</sup> T cells in  
687 patients hospitalized with coronavirus disease 2019. *J. Med. Virol.* (2020).  
688 doi:10.1002/jmv.26213
- 689 33. Braun, J. *et al.* Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and  
690 healthy donors. *medRxiv* (2020). doi:10.1101/2020.04.17.20061440
- 691 34. Liu, W. J. *et al.* T-cell immunity of SARS-CoV: Implications for vaccine development  
692 against MERS-CoV. *Antiviral Res.* **137**, 82–92 (2017).
- 693 35. Lu, R. *et al.* Genomic characterisation and epidemiology of 2019 novel coronavirus:  
694 implications for virus origins and receptor binding. *Lancet (London, England)* **395**, 565–  
695 574 (2020).
- 696 36. Shomuradova, A. S. *et al.* SARS-CoV-2 epitopes are recognized by a public and diverse  
697 repertoire of human T cell receptors. *Immunity* (2020).  
698 doi:10.1016/j.immuni.2020.11.004
- 699 37. Peng, Y. *et al.* Broad and strong memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells induced by SARS-  
700 CoV-2 in UK convalescent individuals following COVID-19. *Nat. Immunol.* **21**, 1336–  
701 1345 (2020).
- 702 38. Xie, X. *et al.* An Infectious cDNA Clone of SARS-CoV-2. *Cell Host Microbe* **27**, 841-  
703 848.e3 (2020).
- 704 39. Muruato, A. E. *et al.* A high-throughput neutralizing antibody assay for COVID-19  
705 diagnosis and vaccine evaluation. *bioRxiv Prepr. Serv. Biol.* Accepted at Nat Comun.  
706 (2020). doi:bioRxiv: 10.1101/2020.05.21.109546

- 707 40. Moodie, Z., Huang, Y., Gu, L., Hural, J. & Self, S. G. Statistical positivity criteria for  
708 the analysis of ELISpot assay data in HIV-1 vaccine trials. *J. Immunol. Methods* **315**,  
709 121–32 (2006).
- 710 41. Moodie, Z. *et al.* Response definition criteria for ELISPOT assays revisited. *Cancer*  
711 *Immunol. Immunother.* **59**, 1489–501 (2010).
- 712 42. Abelin, J. G. *et al.* Mass Spectrometry Profiling of HLA-Associated Peptidomes in  
713 Mono-allelic Cells Enables More Accurate Epitope Prediction. *Immunity* **46**, 315–326  
714 (2017).
- 715 43. Poran, A. *et al.* Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass  
716 spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes.  
717 *Genome Med.* **12**, 70 (2020).
- 718 44. Svitek, N. *et al.* Use of ‘one-pot, mix-and-read’ peptide-MHC class I tetramers and  
719 predictive algorithms to improve detection of cytotoxic T lymphocyte responses in cattle.  
720 *Vet. Res.* **45**, 50 (2014).
- 721 45. Leisner, C. *et al.* One-pot, mix-and-read peptide-MHC tetramers. *PLoS One* **3**, e1678  
722 (2008).
- 723 46. Hadrup, S. R. *et al.* Parallel detection of antigen-specific T-cell responses by  
724 multidimensional encoding of MHC multimers. *Nat. Methods* **6**, 520–6 (2009).
- 725 47. U.S. Department of Health and Human Services, Administration, F. and D. & Research,  
726 C. for B. E. and. Toxicity grading scale for healthy adult and adolescent volunteers  
727 enrolled in preventive vaccine clinical trials. (2007). Available at:  
728 [https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical)  
729 [grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical)  
730 [clinical.](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical)

731 **Figures**




732

733 **Figure 1 | BNT162b2-induced IgG concentrations and virus neutralisation titers.**

734 Vaccination schedule and serum sampling are described in Extended Data Fig. 1. Participants  
 735 were immunised with BNT162b2 on days 1 and 22 ( $n=12$  per dose cohort; from day 22 onwards  
 736  $n=11$  for the 1  $\mu\text{g}$  and 10  $\mu\text{g}$  dose cohorts). Arrowheads indicate days of vaccination. Pre-dose  
 737 responses across all dose levels were combined. COVID-19 human convalescent samples  
 738 (HCS,  $n=38$ ) were obtained at least 14 days after PCR-confirmed diagnosis and at a time when  
 739 the donors were no longer symptomatic. Each serum was tested in duplicate and geometric  
 740 mean concentrations (GMCs) (**a**) and titers (GMTs) (**b**, **e**) were plotted. For values below the  
 741 lower limit of quantification (LLOQ; 1.27 [**a**], 20 [**b**], 300 [**c**]), LLOQ/2 values were plotted.  
 742 Group GMCs or GMTs (values above bars) with 95% confidence interval. **a**, Recombinant S1-  
 743 binding IgG GMC. **b**, SARS-CoV-2 50% neutralisation titers ( $\text{VNT}_{50}$ ) in immunised  
 744 participants and HCS. **c**, Nonparametric Spearman correlation of recombinant S1-binding IgG  
 745 GMCs (as in [**a**]) with  $\text{VNT}_{50}$  from day 29 sera (as in [**b**]) with data points for participants with  
 746 GMCs and GMTs below the LLOQ (open circles) excluded. **d**, Pseudovirus 50% neutralisation

747 titers (pVNT<sub>50</sub>) across a pseudovirus panel displaying 19 SARS-CoV-2 S variants including 18  
748 RBD mutants and the dominant S variant D614G (dose levels 10, 30 and 50 µg, *n*=1-2  
749 representative sera each; day 29).




750

751 **Figure 2 | Incidence and magnitude of BNT162b2-induced T cell responses.**

752 PBMCs obtained on day 1 (pre-prime) and day 29 (7 days post-boost) (dose cohorts 1, 10 and  
 753 20 µg,  $n=9$  each; 30 µg,  $n=10$ ) were enriched for CD4<sup>+</sup> or CD8<sup>+</sup> T cell effectors and separately  
 754 stimulated over night with three overlapping peptide pools representing different portions of  
 755 the wild-type sequence of SARS-CoV-2 S (N-terminal pools S pool 1 and RBD, and the C-  
 756 terminal S pool 2), for assessment in direct ex vivo IFN $\gamma$  ELISpot. Common pathogen T cell  
 757 epitope pools CEF (immune dominant HLA class I epitopes of CMV, EBV, influenza virus)  
 758 and CEFT (immune dominant HLA class II epitopes CMV, EBV, influenza virus, tetanus  
 759 toxoid) were used as controls. Cell culture medium served as negative control. Each dot  
 760 represents the normalised mean spot count from duplicate wells for one study participant, after  
 761 subtraction of the medium-only control (a, c). a, Antigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell  
 762 responses for each dose cohort. The number of participants with a detectable T cell response on  
 763 day 29 over the total number of tested participants per dose cohort is provided. Spot count data  
 764 from two participants from the 20 µg dose cohort could not be normalised and are not plotted.  
 765 b, Example of CD4<sup>+</sup> and CD8<sup>+</sup> ELISpot for a 30 µg dose cohort participant. c, S-specific T cell

766 responses in all participants who recognised either S peptide pool and their baseline CEFT- and  
767 CEF-specific T cell responses. Horizontal bars indicate median values.




768

769 **Figure 3 | Cytokine polarisation of BNT162b2-induced T cells.**

770 PBMCs obtained on day 1 (pre-prime) and day 29 (7 days post-boost) (dose cohorts 1  $\mu$ g,  $n=8$ ;  
 771 10 and 30  $\mu$ g,  $n=10$  each; 20  $\mu$ g,  $n=9$ ) and COVID-19 recovered donors (HCS,  $n=18$ ; **c, d**) were  
 772 stimulated over night with three overlapping peptide pools representing different portions of  
 773 the wild-type sequence of SARS-CoV-2 S (N-terminal pools S pool 1 [aa 1-643] and RBD [aa 1-  
 774 16 fused to aa 327-528 of S], and the C-terminal S pool 2 [aa 633-1273]), and analysed by flow  
 775 cytometry (for gating strategy see Supplementary Fig. 1). **a**, Example of pseudocolor flow  
 776 cytometry plots of cytokine-producing CD4<sup>+</sup> and CD8<sup>+</sup> T cells from a 30  $\mu$ g dose cohort  
 777 participant in response to S pool 1. **b**, S-specific CD4<sup>+</sup> T cells producing the indicated cytokine  
 778 as a fraction of total cytokine-producing S-specific CD4<sup>+</sup> T cells in response to S pool 1 and S



779 pool 2. CD4 non-responders (<0.03% total cytokine producing T cells: 1 µg,  $n=2$  [S pool 1]  
780 and  $n=1$  [S pool 2]; 10 µg,  $n=1$ ) were excluded. Arithmetic mean with 95% confidence interval.  
781 **c**, S-specific CD4<sup>+</sup> (S pool 1, S pool 2 and RBD) and **d**, CD8<sup>+</sup> T cells (S pool 1, S pool 2 and  
782 RBD) producing the indicated cytokine as a fraction of total circulating T cells of the same  
783 subset. Values above data points indicate mean fractions per dose cohort. Participant PBMCs  
784 were tested as single instance (**b-d**).




785

786 **Figure 4 | Characterization of BNT162b2-induced T cells on the single epitope level.**

787 PBMCs obtained on day 1 (pre-prime) and day 29 (7 days post-boost) of three vaccinated  
 788 participants (dose cohorts 10 µg, *n*=1; 30 µg, *n*=2) were stained with individual pMHC class I  
 789 multimer cocktails and analysed for T cell epitope specificity (**a**) and phenotype (**b**; example  
 790 from participant 3; YLQPRTFLL) by flow cytometry (for gating strategy see Supplementary  
 791 Fig. 2). Peptide sequences above dot plots indicate pMHC class I multimer epitope specificity,  
 792 numbers above dot plots indicate the amino acids corresponding to the epitope within S. **c**,  
 793 Localization of identified MHC class I-restricted epitopes within S.


## 794 Extended Data Figures and Tables



795

### 796 Extended Data Figure 1 | Schedule of vaccination and assessment.

797 Study participants received a priming immunisation with BNT162b2 on day 1, and a booster  
798 immunisation on day 22±2. Serum was obtained on days 1 (pre-prime), 8±1 (post-prime), 22±2  
799 (pre-boost), 29±3, 43±4, 50±4 and 85±7 (post-boost). PBMCs were obtained on days 1 (pre-  
800 prime) and 29±3 (post-boost).




801

802 **Extended Data Figure 2 | Solicited adverse events.**

803 Number of participants with local (a) or systemic solicited adverse events (AE) (b). Participants  
 804 were immunised with BNT162b2 on days 1 and 22 (prime:  $n=12$  per dose cohort; boost: 1,  
 805 10 µg,  $n=11$ ); discontinuation of participants due to non-vaccine related reasons). Grey shading  
 806 indicates number of participants at each time point. As per protocol, AEs were recorded up to  
 807 7 days after each immunisation (days 1-7 and 22-28) to determine reactogenicity; for some


808 participants, 1-3 additional days of follow-up were available. Grading of adverse events was  
809 performed according to US Food and Drug Administration (FDA) recommendations<sup>47</sup>.



810

### 811 **Extended Data Figure 3 | Pharmacodynamic markers.**


812 Participants were immunised with BNT162b2 on days 1 and 22 ( $n=12$  per dose cohort). One  
813 participant in the 1 µg dose cohort (outlier on day 8 in [a] and highest data set in [b]) presented  
814 with a non-treatment related gastroenteritis on days 6 to 8. **a**, Kinetics of C-reactive protein  
815 (CRP) level. **b**, Kinetics of lymphocyte counts. **c**, Kinetics of neutrophil counts. Dotted lines  
816 indicate upper and lower limit of reference range. For values below the lower limit of  
817 quantification (LLOQ) = 0.3, LLOQ/2 values were plotted (**a**).



818

819 **Extended Data Figure 4 | BNT162b2-induced RBD-specific IgG concentrations.**

820 Recombinant RBD-binding IgG geometric mean concentration in participants immunised with  
 821 BNT162b2 on days 1 and 22 ( $n=12$  per dose cohort; from day 22 onwards  $n=11$  for the 1 µg  
 822 and 10 µg dose cohorts). Vaccination schedule and serum sampling are described in Extended  
 823 Data Fig. 1. Arrowheads indicate days of vaccination. Pre-dose responses across all dose levels  
 824 were combined. COVID-19 convalescent samples (HCS,  $n=38$ ) were obtained at least 14 days  
 825 after PCR-confirmed diagnosis and at a time when the donors were no longer symptomatic.  
 826 Each serum was tested in duplicate and geometric mean concentrations plotted. For values  
 827 below LLOQ = 1.15, LLOQ/2 values were plotted. Group geometric mean concentrations  
 828 (values above bars) with 95% confidence interval.




829

830 **Extended Data Figure 5 | BNT162b2-induced S-specific CD8 $^+$  and CD4 $^+$  T cells.**

831 CD4 $^+$  or CD8 $^+$  T cell effector-enriched fractions of immunised participants derived from  
 832 PBMCs obtained on day 1 (pre-prime) and day 29 (7 days post-boost) (1, 10 and 20  $\mu$ g dose  
 833 cohorts,  $n=9$  each; 30  $\mu$ g dose cohort,  $n=10$ ) were stimulated overnight with two overlapping  
 834 peptide pools covering the wild-type SARS-CoV-2 S (S pool 1 and S pool 2) for assessment in  
 835 direct ex vivo IFN $\gamma$  ELISpot (**a-c**). Each dot represents the normalised mean spot count from  
 836 duplicate wells for one study participant, after subtraction of the medium-only control. T cell  
 837 responses against S pool 1 and S pool 2 per participant were combined. Spot count data from  
 838 two participants from the 20  $\mu$ g dose cohort could not be normalised and are not plotted.  
 839 PBMCs from vaccinated participants on day 29 (7 days post-boost) (dose cohorts 1  $\mu$ g,  $n=7$ ;  
 840 10 and 30  $\mu$ g,  $n=10$ ; 20  $\mu$ g,  $n=9$ ) were stimulated as described above and analysed by flow  
 841 cytometry (**d, e**). **a**, S-specific CD4 $^+$  and CD8 $^+$  T cell responses for each dose cohort. Number  
 842 of participants with detectable T cell response on day 29 over the total number of tested  
 843 participants per dose cohort is provided. **b**, Mapping of vaccine-induced responses of



844 participants with evaluable baseline data ( $n=34$  for  $CD4^+$  and  $n=37$  for  $CD8^+$  T cell responses)  
845 to different portions of S. De novo induced or amplified responses are classified as BNT162b2-  
846 induced response; no responses or pre-existing responses that were not amplified by the  
847 vaccinations are classified as no vaccine response (none). **c**, Response strength to S pool 1 in  
848 individuals with or without a pre-existing response to S pool 2. Data from the 1  $\mu$ g dose cohort  
849 are excluded, as no baseline response to S pool 2 was present in this dose cohort. Horizontal  
850 bars represent median of each group. **d**, Examples of pseudocolor flow cytometry plots of  
851 cytokine-producing  $CD4^+$  and  $CD8^+$  T cells from a participant prime/boost vaccinated with  
852 30  $\mu$ g BNT162b2. **e**, Frequency of vaccine-induced, S-specific  $IFN\gamma^+$   $CD4^+$  T cells vs.  $IL4^+$   
853  $CD4^+$  T cells. ICS stimulation was performed using a peptide mixture of S pool 1 and S pool 2.  
854 Each data point represents one study participant (1  $\mu$ g dose cohort,  $n=8$ ; 20  $\mu$ g dose cohort,  
855  $n=8$ ; 10 and 30  $\mu$ g,  $n=10$  each). One participant from the 20  $\mu$ g dose cohort with a strong pre-  
856 existing  $CD4^+$  T cell response to S pool 2 was excluded. **f**, Antigen-specific  $CD8^+$  T cell  
857 frequencies determined by pMHC class I multimer staining (% multimer<sup>+</sup> of  $CD8^+$ ), ICS and  
858 ELISpot (%  $IFN\gamma^+$  of  $CD8^+$ ) for the three participants analysed in Figure 4. Signals for S pool  
859 1 and S pool 2 were merged.



860

## 861 Extended Data Figure 6 | Correlation of antibody and T cell responses.

862 Data are plotted for all prime/boost vaccinated participants (dose cohorts 1, 10, 20 and 30  $\mu$ g)  
863 from day 29, with data points for participants with no detectable T cell response (open circles;  
864 **b, c**) excluded from correlation analysis. S1-specific IgG responses as in Fig. 1a, S-specific T  
865 cell responses as in Extended Data Fig. 5a ( $n=37$ ). Nonparametric Spearman correlation. **a**,  
866 Correlation of S1-specific IgG responses with S-specific CD4<sup>+</sup> T cell responses. **b**, Correlation  
867 of S-specific CD4<sup>+</sup> with CD8<sup>+</sup> T cell responses. **c**, Correlation of S1-specific IgG responses  
868 with S-specific CD8<sup>+</sup> T cell responses.

869 **Extended Data Table 1 | Demographic characteristics.**

Cohort		1 µg (N=12) n (%)	10 µg (N=12) n (%)	20 µg (N=12) n (%)	30 µg (N=12) n (%)	Total (N=48) n (%)
Sex	Male	7 (58.3)	4 (33.3)	2 (16.7)	8 (66.7)	21 (43.8)
	Female	5 (41.7)	8 (66.7)	10 (83.3)	4 (33.3)	27 (56.2)
Race	Caucasian	12 (100)	12 (100)	12 (100)	12 (100)	48 (100)
	African American	0	0	0	0	0
	Asian	0	0	0	0	0
Age at vaccination (years)	Mean (SD)	36.1 (10.09)	34.8 (10.41)	42.3 (9.86)	46.7 (6.41)	39.9 (10.26)
	Median	37.0	35.5	41.5	47.0	41.0
	Min, Max	21, 53	19, 51	29, 55	35, 55	19, 55

870

871 N, number of participants in the specified group. This value is the denominator for the

872 percentage calculations. n, number of participants with the specified characteristics.

873 **Extended Data Table 2 | Participant disposition and analysis sets.**

Cohort	BNT162b2 vaccinated		Safety analysis		Antibody analysis							T-cell analysis	
	Prime	Boost	Day 1+	Day 22±2+	Day 1	Day 8±1	Day 22±2	Day 29±3	Day 43±4	Day 50±4	Day 85±7	Day 1	Day 29±3
1 µg	12	11	12	11	12	12	12	11	10	10	0	9* (8)	9 (8)
10 µg	12	11	12	11	12	12	11	11	11	11	11	9** (10)	9 (10)
20 µg	12	12	12	12	12	12	12	12	12	12	10	9 (9)	9 (9)
30 µg	12	12	12	12	12	12	12	12	11	12	12	10 (10)	10 (10)

874

875 Twelve participants per dose cohort received the priming and the booster dose except for two  
876 participants, who discontinued prior the booster dose due to a study drug-unrelated withdrawal  
877 by the participant (1 µg dose) and an adverse event (10 µg; upper respiratory syndrome),  
878 respectively. Safety analysis: Number of participants for whom 7 days of reactogenicity follow-  
879 up after both doses was evaluable at data cut-off. Antibody analysis: Numbers of participants  
880 for whom virus neutralisation assays and S1- and RBD-binding IgG antibody assays were  
881 performed. T cell analysis: Numbers of participants for whom PBMCs were available at data  
882 cut-off and IFN $\gamma$  ELISpot and flow cytometry (in parentheses). N/A, not applicable. \*8 and \*\*7  
883 for CD4<sup>+</sup> T cell responses.

884 **Extended Data Table 3a | Summary of solicited local reactions.**

Time interval		1 µg (N=12)	10 µg (N=12)	20 µg (N=12)	30 µg (N=12)	Total (N=48)
Dose 1 up to day 7 after dose 1	nn	12	12	12	12	48
	Any local reaction, n (%)	6 (50)	12 (100)	12 (100)	10 (83)	40 (83)
	Any grade ≥3 local reaction, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Dose 2 up to day 7 after dose 2	nn	11	11	12	12	46
	Any local reaction, n (%)	4 (36)	10 (91)	10 (83)	11 (92)	35 (76)
	Any grade ≥3 local reaction, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Combined interval	nn	12	12	12	12	48
	Any local reaction, n (%)	7 (58)	12 (100)	12 (100)	11 (92)	42 (88)
	Any grade ≥3 local reaction, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

885

886 **Extended Data Table 3b | Summary of solicited systemic reactions.**

Time interval		1 µg (N=12)	10 µg (N=12)	20 µg (N=12)	30 µg (N=12)	Total (N=48)
Dose 1 up to day 7 after dose 1	nn	12	12	12	12	48
	Any systemic reaction, n (%)	9 (75)	12 (100)	9 (75)	9 (75)	39 (81)
	Any grade ≥3 systemic reaction, n (%)	0 (0)	0 (0)	1 (8)	0 (0)	1 (2)
Dose 2 up to day 7 after dose 2	nn	11	11	12	12	46
	Any systemic reaction, n (%)	4 (36)	7 (64)	10 (83)	10 (83)	31 (67)
	Any grade ≥3 systemic reaction, n (%)	0 (0)	1 (9)	1 (8)	3 (25)	5 (12)
Combined interval	nn	12	12	12	12	48
	Any systemic reaction, n (%)	9 (75)	12 (100)	11 (92)	12 (100)	44 (92)
	Any grade ≥3 systemic reaction, n (%)	0 (0)	1 (8)	2 (17)	3 (25)	6 (13)

887

888 The combined interval is the union of the intervals ‘Dose 1 up to day 7 after dose 1’ and ‘Dose  
889 2 up to day 7 after dose 2’. N = number of participants in the analysis set; n = number of  
890 participants with the respective local (a) or systemic (b) reactions; nn = number of participants  
891 with any information on local (a) or systemic (b) reactions available.